Critical reviews in clinical laboratory sciences最新文献

{"title":"The sex difference in plasma cystatin C is age-dependent: a systematic review and meta-analysis.","authors":"Filip Landgren, Bertil Kågedal, Eva Landberg","doi":"10.1080/10408363.2026.2640949","DOIUrl":"10.1080/10408363.2026.2640949","url":null,"abstract":"<p><p>Cystatin C-based GFR equations (eGFR_cys) are inconsistent; some include a sex-adjustment factor while others do not. This reflects ongoing uncertainty about whether cystatin C concentrations differ between sexes in healthy individuals without kidney disease and how any such difference varies with age. We performed a systematic review and meta-analysis to address this discrepancy. We conducted a PRISMA-compliant systematic review (PubMed, Scopus, Embase) of studies reporting sex-specific cystatin C data in healthy adults. From 21 studies comprising more than 46,000 healthy adults, 52 unique subgroups (<i>k</i> = 52) were extracted. Analyses comprised: (1) a meta-regression of all subgroups by mean age; (2) a random-effects model for younger and middle-aged adults (<i>k</i> = 32, age ≤ 60 years); and (3) a separate model for older adults (<i>k</i> = 13, age ≥ 60 years). A qualitative review of pediatric data provided life-course context. The qualitative pediatric review confirmed a consistent 12-15% sex difference (men > women) emerging during adolescence. In younger and middle-aged adults, men had 8.6% higher cystatin C concentrations than women (pooled M/F ratio 1.0860, 95% CI 1.0587-1.1133; <i>p</i> < .0001). In older adults, this difference was markedly attenuated (M/F ratio 1.0338, 95% CI 1.0132-1.0544). Across all adult subgroups, meta-regression indicated an age-related attenuation of the sex difference (β = -0.0011 per year). Between-study heterogeneity was substantial (I² = 98% in younger adults, 76% in older adults), likely reflecting true variability in population characteristics and analytical methods; however, the direction of the sex difference was highly consistent across studies. Sensitivity analyses using robust variance estimation, leave-one-out analysis, and trim-and-fill methods confirmed the robustness of pooled estimates and found no evidence of substantial publication bias. Plasma cystatin C exhibits a consistent, biologically plausible sex difference that varies across the life course, with a pronounced difference in adolescence and early to mid-adulthood that attenuates after 60 years of age. This pattern coincides with age-related changes in sex hormone exposure and, together with experimental and clinical evidence, supports a hormonal contribution to cystatin C regulation. These findings challenge the validity of both sex-neutral eGFR_cys equations, which may underestimate kidney function in younger men, and uniform sex-adjustment equations, which may overcorrect in older adults. Our results support the development of age-dependent, sex-specific approaches to cystatin C-based kidney function assessment.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"521-541"},"PeriodicalIF":6.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complex relationship between oxidative stress and aging: new perspectives on similarities and differences.","authors":"Xue-Song Liu, Chenglong Zhu, Haoling Zhang, Wangzheqi Zhang","doi":"10.1080/10408363.2026.2651307","DOIUrl":"10.1080/10408363.2026.2651307","url":null,"abstract":"<p><p>The association of oxidative stress with aging is considered one of the key theoretical cornerstones in aging research, but accumulating evidence has cast some doubt on the validity of a single \"cumulative oxidative damage\" hypothesis as its mechanism. This review aims to provide a comprehensive and updated overview of the complex interplay between oxidative stress and aging, with a particular focus on their shared mechanisms and context-dependent effects. ROS should not be regarded only as deleterious metabolic waste, but indeed act as pivotal signaling mediators in metabolic, stress, and cell fate regulation within the frame of physiological ranges. In addition, emerging evidence highlights the dual roles of ROS in maintaining cellular homeostasis and mediating stress responses depending on their concentration and spatial distribution. Only when the fine-tuned equilibrium that usually couples ROS production and disposal is perturbed and quality-control activity becomes defective does this signaling network gradually shift from a physiological into a pathological source of stress promoting cellular senescence and tissue malfunction. Aging should thus be considered the outcome of structural derangement in homeostatic regulatory networks caused by chronic stress. This view of the aging process is developed through a discussion of key events comprising oxidative DNA damage, mitochondrial dysfunction, decline in autophagy and lysosomal degradation, as well as senescent cell secretion (SASP), indicating that their reciprocal interactions together define phenotypic features characterizing the aging cell. This network-centric model further mechanistically justifies why peripheral effects of broad-spectrum antioxidant interventions are heterogeneous, and points to rolling back the damage with compensatory quality-control mechanisms and homeostatic regulation as a more effective path toward understanding how to restore homeostasis. These insights may contribute to the development of more precise therapeutic strategies targeting aging-related diseases and improving healthspan. Future research should further clarify the spatiotemporal dynamics of ROS signaling and its integration with cellular stress-response networks. Moreover, elucidating the threshold-dependent and context-specific effects of oxidative signaling may provide a conceptual basis for precision interventions in aging and age-related diseases.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"588-620"},"PeriodicalIF":6.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical result thresholds and notification practices in clinical laboratories.","authors":"Kobe Truijens, Tejas Kalaria, Vincent De Guire, Alexander von Meyer, Pieter Vermeersch","doi":"10.1080/10408363.2026.2718329","DOIUrl":"https://doi.org/10.1080/10408363.2026.2718329","url":null,"abstract":"<p><p>Laboratory medicine plays an important role in clinical decision-making. The timely notification of results requiring medical attention is therefore essential to ensure patient safety. Since its introduction, the concept of critical result notification has expanded to include both critical decision limits and significant abnormal results. To avoid overlooking such results, most laboratories use alert lists consisting of predefined thresholds programmed into the laboratory information system. Despite widespread adoption, considerable variability persists in alert lists used across laboratories. Differences in patient populations and healthcare settings partly explain variation in alert thresholds, acceptable notification delays, communication modalities, and the designated recipients of notifications. Telephone communication remains the predominant modality for notifying critical results, although electronic medical record-based alerts are increasingly being implemented. Persistent challenges include notification fatigue, communication delays, and inconsistent follow-up actions. Quality indicators should therefore address not only the timeliness of notification but also the timeliness of the clinical response. Looking ahead, the integration of structured clinical and laboratory data, together with emerging artificial intelligence tools, holds promise for developing more personalized and clinically meaningful notification policies.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"1-9"},"PeriodicalIF":6.2,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and monitoring of metabolic dysfunction-associated steatohepatitis disease: a critical review.","authors":"Elisa Marin-Couture, Fannie Lajeunesse-Trempe, Georgios K Dimitriadis, Royce P Vincent","doi":"10.1080/10408363.2026.2716664","DOIUrl":"https://doi.org/10.1080/10408363.2026.2716664","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide and includes a spectrum ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, and cirrhosis. Given the heterogeneous nature of disease progression and the central role of fibrosis predicting local or systemic clinical outcomes (e.g. liver cirrhosis, hepatocarcinoma, cardiovascular diseases), early identification and longitudinal monitoring of individuals at risk is crucial. However, current diagnostic tools present important limitations, particularly across diverse metabolic profiles such as individuals living with obesity or type 2 diabetes. Therefore, this review provides a comprehensive overview of current diagnostic and monitoring strategies for MASLD and MASH, including routine biochemical markers, noninvasive steatosis and fibrosis scores, imaging modalities, and liver biopsy. Multimodal and individualized diagnostic approaches integrating clinical, metabolic, imaging, and molecular data appear essential to improve early detection, refine longitudinal monitoring, and support precision-based management of MASLD.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"1-19"},"PeriodicalIF":6.2,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laboratory information system implementation and electronic health record integration: challenges, opportunities, and practical strategies.","authors":"Li Zha","doi":"10.1080/10408363.2026.2712373","DOIUrl":"https://doi.org/10.1080/10408363.2026.2712373","url":null,"abstract":"<p><p>The laboratory information system (LIS) is an indispensable component of the modern clinical laboratory, underpinning day-to-day operations and playing a critical role in delivering quality patient care. Clinical laboratories are challenged to introduce new technologies within steady-state staffing, including navigating the complex process of implementing a new LIS. In recent years, a growing number of laboratories are transitioning to systems integrated within the EHR. The complexity increases further when LIS and EHR go live simultaneously, a scenario that is particularly challenging in integrated health systems. This review synthesizes the current literature as well as real-world experiences and lessons from the planning, build/validation, rollout readiness, stabilization, and optimization phases to offer practical strategies and operational insights for clinical laboratories undertaking LIS implementation, with particular attention to the unique considerations of concurrent EHR/LIS rollouts. Opportunities for future developments are also highlighted.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"1-19"},"PeriodicalIF":6.2,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interplay between chronic inflammation and tumorigenesis: unraveling the inflammation-driven axis.","authors":"Wangzheqi Zhang, Lizhou Song, Doblin Sandai, Zhiheng Lin","doi":"10.1080/10408363.2026.2713153","DOIUrl":"https://doi.org/10.1080/10408363.2026.2713153","url":null,"abstract":"<p><p>Chronic inflammation is now recognized as an important factor linking tissue damage to the development of cancer. Epidemiological studies have suggested that 20%-25% of cancers are related to chronic inflammation, as exemplified by chronic hepatitis B infection inducing hepatocellular carcinoma (HCC) or Helicobacter pylori infection inducing the development of gastric cancer. In chronic inflammation, an overexpression of signaling pathways such as NF-κB, JAK/STAT3, MAPK and NLRP3 at the molecular level leads to continuous upregulation of the secretion of pro-inflammatory cytokines and immune-metabolic reprogramming. These processes result in DNA damage, genetic mutations and epigenetic changes, promoting the initiation and progression of tumors. Interactions between pro-inflammatory cytokines and different types of cellular constituents reshape the tumor microenvironment (TME), leading to fibrosis, chaotic angiogenesis, and immune suppression-favoring further immune escape by tumors and perpetuating cancer stemness. Furthermore, through epigenetic as well as other molecular mechanisms, chronic inflammation fosters tumor drug resistance. So far, anti-inflammatory agents (e.g. anti-inflammatory drugs and natural bioactive compounds) as well as forms of dietary intervention have been associated with a reduced risk of cancer development in selected inflammation-associated settings, emphasizing that inflammation control may contribute to cancer prevention when supported by appropriate patient selection and clinical validation. In addition, new anti-inflammatory drug interventions targeting the IL-6/STAT3, NF-κB and NLRP3 pathways have shown good prospects for inhibiting tumors while modulating the immune microenvironment. Inflammatory biomarkers and epigenetic inflammation scores may support cancer risk stratification, early detection, prognostic assessment and treatment monitoring; however, most should be interpreted as complementary laboratory tools rather than stand-alone diagnostic tests, and their clinical implementation requires standardized analytical platforms, harmonized cutoff values, demonstration of incremental utility and prospective validation.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"1-34"},"PeriodicalIF":6.2,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of blood biomarkers for excluding head CT abnormalities after mild traumatic brain injury in adults: a systematic review and meta-analysis.","authors":"Lara Milevoj Kopčinović, Chiara Di Resta, Sanja Stanković, Aurelie Ladang, Anne-Cécile Chiollaz, Helena Ferreira da Silva, Vincent Sapin, Tomris Ozben","doi":"10.1080/10408363.2026.2708643","DOIUrl":"https://doi.org/10.1080/10408363.2026.2708643","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Traumatic brain injury (TBI) is a major cause of mortality and long-term disability, and mild TBI accounts for more than 90% of hospital-presenting cases. Diagnostic management of mild TBI relies on clinical assessment and neuroimaging, with non-contrast head computed tomography (CT) representing the diagnostic standard for detecting acute intracranial abnormalities. Nevertheless, approximately 90% of CT scans performed in mild TBI show no intracranial injury. Blood biomarkers have emerged as objective measures of brain injury for identifying patients at low probability of CT-detectable injury. We conducted a systematic review and diagnostic test accuracy meta-analysis to evaluate blood biomarkers measured using automated analytical platforms for excluding CT-detectable intracranial abnormalities in adults with mild TBI. The review was conducted according to PRISMA-DTA guidelines and registered in PROSPERO (CRD420251087456). PubMed/MEDLINE, Embase, Web of Science, Cochrane Library, Scopus, Science Citation Index and Google Scholar were searched for studies published from January 2010 to December 2025. Eligible studies enrolled adults with mild TBI (Glasgow Coma Scale score 13-15), biomarkers measured within 24 h of injury using commercially available automated assays and non-contrast head CT used as the reference standard. Methodological quality was assessed using QUADAS-2. Pooled sensitivity and specificity were estimated using bivariate random-effects models, and heterogeneity was explored using meta-regression. Thirty studies including more than 15,000 patients were included. Eligible evidence was available only for S100B, glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCH-L1), and combined biomarkers GFAP and UCH-L1. No eligible studies evaluating neuron-specific enolase, neurofilament light chain or other biomarkers met the predefined criteria. S100B showed high pooled sensitivity of 92% (95% CI 89-94%) but low specificity of 31% (95% CI 27-35%). GFAP alone showed pooled sensitivity of 89% (95% CI 83-93%) and specificity of 37% (95% CI 27-48%), whereas UCH-L1 alone showed lower sensitivity of 72% (95% CI 62-80%) and specificity of 53% (95% CI 47-59%). The combination of GFAP and UCH-L1 demonstrated the highest pooled sensitivity of 94% (95% CI 92-95%) but lowest specificity of 28% (95% CI 23-33%). Specificity showed substantial heterogeneity across biomarkers. Meta-regression suggested that earlier sampling improved S100B sensitivity, while age was associated with specificity for the combined biomarkers GFAP and UCH-L1. Sensitivity analyses excluding high risk of bias studies did not substantially change the pooled estimates, and Deeks' funnel plot did not indicate significant small-study effects. Blood biomarkers measured using automated platforms showed clinically meaningful rule-out potential for CT-detectable intracranial abnormalities in adults with mild TBI. Specifically, the results of our diagnostic ","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"1-20"},"PeriodicalIF":6.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiota and tumor epigenetics: deep interconnections and emerging therapeutic perspectives.","authors":"Lei Duan, Dan Hu, Haoling Zhang, Yan Liao","doi":"10.1080/10408363.2025.2602551","DOIUrl":"10.1080/10408363.2025.2602551","url":null,"abstract":"<p><p>Cancer is a major global public health problem. Epigenetic regulation, such as DNA methylation, histone modifications, and non-coding RNA (ncRNA) dysregulation, is a main driver of tumorigenesis and progression. Recent studies are suggesting that the human microbiota, commonly referred to as a \"super-organ,\" are not only associated with tumors but play an active role in regulating the epigenetic state of the host. The aim of this review is to systematically explain the main regulatory mechanisms of the \"microbiota-epigenetic-cancer regulatory axis\", their heterogeneous manifestations across various tumors, and the exploration of novel diagnostic biomarkers and therapeutic strategies of this regulatory axis. Microbiota mainly drive tumor epigenetic remodeling through three levels. First, microbial metabolites (e.g., butyrate) can act as natural histone deacetylase inhibitors (HDACis), or tryptophan metabolites can directly regulate the host chromatin state by activating the aryl hydrocarbon receptor (AhR) pathway. Second, bacterial structures such as lipopolysaccharide (LPS) can induce inflammation and disease by activating inflammatory signaling pathways. Third, specific pathogens like HBV and <i>Helicobacter pylori</i> can hijack the host's epigenetic machinery or induce epigenetic reprogramming via virulence factors. The tumor-resident microbiota (TRM) is an emerging and important field. TRM that actively partake in the tumor microenvironment (TME) may promote immune evasion through <i>in situ</i> mechanisms (e.g., lactylation), thereby confirming a direct and causal role for microbes within tumors. The epigenetic therapeutic strategies based on these mechanisms are being rapidly developed, including, for example, the regulation of microbial community structure (e.g., FMT), the targeting of microbial metabolic pathways, and TRM-specific approaches and key pathways (e.g., engineered bacteria). These strategies also have great potential as biomarkers for tumor prognosis prediction and therapy response evaluation. Overall, microbes and tumor epigenetics are part of a network that brings together their metabolism, inflammation, immunity, and gene regulation. Future research will shift from exploring the correlation of the gut microbiota at the macro level to exploring TRM's causality within the TME. By using gnotobiotic mouse models, organoid co-cultures, and multiomics, we will deeply analyze the microenvironment specificity of this network and develop precision interventions targeting TRM that could transform cancer therapy.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"433-473"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145905824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of antiphospholipid antibodies on prothrombin time and international normalized ratio: a scoping review.","authors":"Arne Vandevelde, Mohammad Amir, Katrien M J Devreese","doi":"10.1080/10408363.2025.2584522","DOIUrl":"10.1080/10408363.2025.2584522","url":null,"abstract":"<p><p>Antiphospholipid antibodies (aPL) may interfere with prothrombin time (PT) and international normalized ratio (INR) assays. Patients with antiphospholipid syndrome (APS) are often treated with vitamin K antagonists and require therapeutic monitoring with the INR. However, it remains unclear to what extent these assays are influenced by aPL and the consequent clinical relevance. This scoping review aimed to map the available evidence on the impact of APS and aPL on PT/INR assays, describe the methods used in research in this area, and identify gaps to guide future investigations. Two databases (MEDLINE and Embase) were searched, in the date range of 1 January 1984 to 10 June 2025, for reports describing clinical or <i>in vitro</i> research involving human subjects with APS or aPL that were analyzed with INR/PT assays. Results were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping Reviews (PRISMA-Scr) guideline. 3,824 records were retrieved and after deduplication, title/abstract screening, and full-text screening, 39 studies were included in the review. Based on study design, we identified 23 observational clinical studies, 11 case reports/series, and 5 studies reporting <i>in vitro</i> aPL investigations with one report also including a case-control study. Observational studies showed that INR assays utilizing thromboplastin with recombinant human tissue factor (TF), including point-of-care tests (POCT), are more influenced by aPL than assays based on tissue-derived thromboplastins, although not consistently. Case reports described patients, mostly with the presence of multiple aPL, with clinically significant misinterpretation of their anticoagulation status. <i>In vitro</i> studies demonstrated reagent- and antibody-dependent effects, with anti-β2-glycoprotein I and antiprothrombin immunoglobulin G antibodies variably prolonging or shortening the PT. Evidence from both clinical and <i>in vitro</i> studies indicates that INR results in APS patients may be unreliable, particularly with specific recombinant human TF-based and POCT reagents, although not systematically. Interference is antibody profile-, antibody level-, and reagent-dependent. However, studies remain heterogeneous, often small in scale, and methodologically inconsistent with variable evaluation criteria. Well-defined future research should aim to identify in which APS patient subgroups an INR would not be reliable with specific assays.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"415-432"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145660502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One health and laboratory medicine: challenges and perspectives for antimicrobial resistance, emerging infections, and food/water security.","authors":"Marco Ciotti, Sergio Bernardini","doi":"10.1080/10408363.2025.2597189","DOIUrl":"10.1080/10408363.2025.2597189","url":null,"abstract":"<p><p>The One Health Approach recognizes the interconnectedness of human, animal, and environmental health. Emerging infectious diseases, climate change, and food/water insecurity impact all three. Global health improvement requires collaborative, holistic strategies at all levels to mitigate harmful factors and promote sustainable development. This review defines the One Health approach and illustrates its role in combating antibiotic resistance, emerging infectious diseases, and food/water insecurity. Laboratory medicine for both human and veterinary health, as well as environmental monitoring, are crucial in this context.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":" ","pages":"390-402"},"PeriodicalIF":6.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145755512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}